Horizon Technology Finance(US:HRZN)2026-03-04 15:02Financial Data and Key Metrics Changes - The company generated net investment income (NII) of $0.18 per share for Q4 2025, down from $0.32 per share in Q3 2025 and $0.27 per share in Q4 2024 [24] - The net asset value (NAV) per share was $6.98 as of December 31, 2025, compared to $7.12 as of September 30, 2025, and $8.43 as of December 31, 2024 [27] - Total investment income for Q4 was $21 million, compared to $24 million in the prior year period, primarily due to lower interest income on the debt investment portfolio [23] Business Line Data and Key Metrics Changes - The current portfolio stood at $647 million, with new originations totaling $103 million in Q4, offset by $13 million in scheduled principal payments and $15 million in principal prepayments [10][26] - The debt portfolio yield was 14.3% for Q4, down from 14.9% in the previous year's Q4, while onboarding yields were 12% for Q4, consistent with historical levels [12][23] - The company ended the year with a committed and approved backlog of $154 million, an increase from $119 million at the end of Q3 [13] Market Data and Key Metrics Changes - Approximately $92 billion was invested in VC-backed companies in Q4 2025, with 2025 being the largest year of investment since 2021 [15] - The demand for venture debt capital remains high, and the company expects to be a key supplier of such capital in the coming year [9] Company Strategy and Development Direction - The merger with Monroe Capital is expected to significantly increase equity capital available for investment and allow for larger venture loans [5][7] - The company aims to optimize returns and create future value through collaboration with portfolio companies and a disciplined approach to underwriting new loans [14][19] - The focus remains on targeting larger venture loan opportunities for both private and small-cap public companies post-merger [18] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges faced in 2025 but expressed optimism about the groundwork laid for long-term success [4] - The company anticipates that the size of its portfolio and growth expectations will enable it to generate NII that covers distributions over time [25] - The management highlighted the importance of navigating the changing environment, particularly in AI and defense technology sectors [17] Other Important Information - The company redeemed its notes due in 2026 and issued new 7% notes due in 2028 [8] - The company has a strong liquidity position with $189 million in available liquidity as of December 31, 2025 [20] Q&A Session Summary Question: Can you elaborate on the new dividend level decision? - The company reviews distribution levels with the board each quarter, considering the current portfolio, run rate, spillover, and growth opportunities to determine a sustainable level [29][30] Question: What drove the lower interest income? - The lower interest income was primarily due to reduced prepayment activity and the timing of fundings, with significant prepayments occurring in Q3 but only one in Q4 [34][36] Question: What are the opportunities for public company financing? - The company sees opportunities in providing flexible capital structures to companies that may not be profitable and typically resort to equity financing, which is more dilutive [40] Question: Can you provide details on the non-accrual portfolio companies? - The company is working to maximize recoveries on non-accruals, which are at various levels, and has improved the percentage of non-accruals quarter-over-quarter [44][45] Question: What was the driver of the realized loss? - The realized loss included a small position in Tallac Therapeutics, but the overall impact was minimal, with net realized and unrealized results being slightly positive [49][51]